We are very happy to have been able to recruit Dr. Malmborg, who has extensive experience from commercialization of academic results, financial markets and business developments says Prof.Carl Borrebaeck, chairman of the Board of SenzaGen.
Anki Malmborg Hager has more than 20 years´ experience in both pharmaceutical and biotech companies that are spin-offs from the University. She held the position as Investment Director in Lund University Bioscience AB between 2009 and 2011 as well as management positions in eg. Alligator Bioscience AB, XImmune AB (CEO), Cantargia AB (CEO), and Diaprost AB (CEO).
“I am very pleased to have been offered this opportunity” says Anki Malmborg Hager. “The underlying research in SenzaGen is world class and the market window of opportunity is timely and very exciting. I am looking forward to joining the SenzaGen team and to lead the next steps in the commercialization of many years of first-class research”.
For more information please contact:
Carl Borrebaeck, Chairman of the Board, SenzaGen AB
+46 708 218330